There is no universal legal age requirement for taking ashwagandha, but most commercial supplements label the product for adults 18 and older. That said, clinical trials have studied ashwagandha in children as young as 6, and traditional use goes even younger. The real answer depends on the form, the dose, and whether a healthcare provider is involved.
What Supplement Labels Say
Most ashwagandha products sold in the United States carry a standard caution stating that “children under the age of 18 should consult a physician before using this or any dietary supplement.” The NIH’s Dietary Supplement Label Database lists the intended target group for typical ashwagandha products as adults aged 18 to 50. This isn’t a legal restriction. It reflects the fact that supplements are formulated and dosed for adults, and manufacturers want to limit their liability for populations with less safety data.
In Europe, regulators take a more cautious stance. The German Federal Institute for Risk Assessment specifically recommends that children avoid ashwagandha supplements, citing a lack of safety data for that age group. Pregnant and breastfeeding women receive the same warning.
What Clinical Research Shows in Children
Despite the cautious labeling, researchers have tested ashwagandha in children, and the results are informative. A randomized, placebo-controlled trial published in Frontiers in Nutrition gave 85 healthy children aged 6 to 12 a standardized root extract (150 mg twice daily) or a placebo for eight weeks. The children taking ashwagandha showed improvements in memory, processing speed, attention, and parent-reported sleep quality. No serious adverse events were reported, and the mild side effects that did occur, mainly stomach pain, were comparable between the supplement and placebo groups. No child dropped out because of side effects.
A separate study published in the Journal of the American Academy of Child and Adolescent Psychiatry evaluated the same dose (150 mg twice daily) in children aged 6 to 12 with parent-reported problems in cognition, attention, behavior, and sleep. It similarly found improvements in cognition and sleep disturbances, and reported no adverse effects at all.
Older research used higher doses. Two earlier studies gave children aged 8 to 12 about 2 grams per day of ashwagandha root powder for 60 days. Another study included children as young as 3, using traditional formulations at doses between 2.5 and 8 grams daily depending on age. These studies also did not flag significant safety concerns, though they were smaller and less rigorous by modern standards.
Dosing Differences for Younger Users
Adult ashwagandha studies typically use 3 to 5 grams of root powder or 300 to 600 mg of a concentrated extract per day. For children aged 8 to 12, researchers have generally used roughly half the adult dose of root powder (about 2 grams per day). The more recent clinical trials in children aged 6 to 12 used a much lower amount of a standardized extract: 150 mg twice daily, totaling 300 mg per day.
A common starting recommendation for children is 100 to 250 mg per day of a standardized extract, then adjusting based on response. The type of product matters here. A concentrated extract delivers far more active compounds per milligram than raw root powder, so the numbers aren’t directly comparable. Gummy and liquid forms designed for children tend to use lower, more controlled doses than capsules marketed to adults.
Hormonal and Thyroid Considerations
One reason parents hesitate is concern about hormonal effects. In adult men, ashwagandha has been shown to increase testosterone levels, and it reliably lowers cortisol (the body’s main stress hormone) across age groups. There is currently no published research showing that ashwagandha disrupts normal hormonal development during puberty, but there is also no long-term data confirming it doesn’t. This is a genuine gap in the evidence.
Ashwagandha can also influence thyroid hormone levels, which is relevant for children with thyroid conditions or autoimmune disorders. If a child takes thyroid medication or has an autoimmune condition, ashwagandha is generally not recommended without medical clearance.
Practical Guidance by Age Group
- Under 6: Almost no modern clinical data exists for this age group. Traditional Ayurvedic practices have used ashwagandha in children as young as 3, but Western safety evidence is essentially absent.
- Ages 6 to 12: The strongest pediatric evidence falls in this range, with clinical trials showing cognitive and sleep benefits at 300 mg per day of standardized extract over 8 weeks. Side effects were minimal and comparable to placebo. Still, these studies are small, and long-term data beyond a few months doesn’t exist.
- Ages 13 to 17: Surprisingly, this age group has less direct clinical trial data than younger children. Teenagers are physiologically closer to adults, so adult dosing guidelines are sometimes applied, but no published trial has specifically enrolled adolescents.
- 18 and older: This is the age most products are labeled for, and the vast majority of clinical evidence comes from adult populations.
Why the 18-and-Over Label Exists
The age 18 threshold on supplement labels isn’t based on evidence that ashwagandha becomes safe on your 18th birthday. It reflects a regulatory and commercial reality: supplements are classified as food products, not drugs, and manufacturers aren’t required to prove safety in children before selling them. Labeling for adults is the default because that’s where the bulk of the research is, and it reduces legal exposure for the company.
The existing pediatric research suggests ashwagandha can be well tolerated in children at appropriate doses and in studied forms. But “well tolerated in an 8-week trial” is different from “proven safe for long-term use in growing bodies.” The short duration of available studies means questions about extended use during critical developmental windows remain open. For parents considering ashwagandha for a child, working with a provider who can match the dose to the child’s age, weight, and health status is the most reliable path forward.